The Newsroom

Investigations  /  11.10.2020

Investigation of Evolus, Inc.

You Have Legal Options

Evolus, Inc. (EOLS) Misappropriated Trade Secrets     

Beginning in February 2019, Evolus began a campaign in which it promoted Jeuveau™ as a proprietary formulation of the botulinum toxic type A complex, purportedly developed by a Korean bioengineering company through years of clinical research.  On July 6, 2020, the U.S. International Trade Commission (“ITC”) issued its Initial Final Determination in a case brought by Allergan, the U.S. manufacturer of Botox, and Medytox, the Korean manufacturer of a similar product, against Evolus, which claimed that Evolus stole trade secrets to develop Jeuveau. The ITC Judge determined that Evolus and its South Korean partner firm misappropriated the botulinum toxin and the manufacturing process that led to its development and manufacture.  As a result, the ITC Judge recommended a ten-year long ban on Evolus’ ability to import and sell Jeuveau in the United States. On this news, Evolus’ stock dropped 37% in two days to close at $3.35 on July 8, 2020 and has yet to recover.

If you purchased Evolus, Inc. (EOLS) securities between February 1, 2019 and July 6, 2020, you have legal options.  Please reach out to Robbins LLP for more information. 

  • If you would like more information about your rights and potential remedies please send us a message. 

  • Please Note: Neither the submission to nor the receipt of information by Robbins LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.


How can we help you?

CONTACT US TODAY | 1 800 350 6003 or [email protected]

Tell us your concerns